GLP-1 Cost Crisis Brief

The Hidden Threat to Your Pharmacy Budget

“Employers may spend up to $12,500 per GLP-1 user annually.”

(Source: CDC, PBM Data)

GLP-1 drugs like Ozempic and Wegovy are gaining popularity fast, driven by employee demand for weight loss and diabetes management. For many employers, these rising claims could quietly and quickly drive millions in unexpected pharmacy spend.

Here’s The Reality

Key Takeaways

✓ GLP-1 costs will grow 10-14% annually as coverage becomes mandatory and adoption increases
✓ Pharmaceutical-only approaches create long-term dependency without addressing behavioral root causes
✓ Evidence-based lifestyle interventions reduce diabetes/obesity risk more effectively than medication alone
✓ Fresh Tri's brain-based approach tackles motivation and habit formation challenges that cause pharmaceutical reliance
✓ Upstream behavioral investment delivers downstream pharmaceutical cost mitigation with documented ROI

GLP-1 Cost Exposure at Scale

The Question for Employers:

Can you afford NOT to address root causes when the pharmaceutical-only approach will cost you $69M over the next 5 years?

Stop paying for your population to lose the same 10 pounds every year

Instead of seeing up to 99% relapse, deliver lasting results that lower your healthcare costs.

Long-Term habit transformation

Neuroscience-based mindset training

Traditional Behavior Change Methods

Rigid short-term goals

Tracking incentives, comparisons

Fresh Tri offers a way oput of being on GLP-1s for life

Our brain-based approach offers a path to freedom from GLP-1 long-term dependance

+27,000

Potential savings per patient even without a GLP-1*

To mantain weright loss results current GLP-1 therapies must be continued indefinitely

+12,588

Annual Cost Per Patient (when on a GLP-1)

How can organizations manage budgets when costs are rising?

Most benefit plans aren’t prepared for the spend surge, but there is a proven, science-backed way to reduce the cost at the source.

How to Control GLP-1 Costs Beyond the Pharmacy Benefit

Yes, plan design tweaks can help, but the biggest cost-control lever is reducing GLP-1 demand at the source: daily behavior and habits. Fresh Tri’s Iterative Mindset Method™ uses neuroscience, not willpower, to help employees form sustainable habits. The IMM leverages proven strategies without the disappointment of short-term gain and relapse offered by traditional methods.

Key Takeaway

Behavior Change Works Up to 30% of GLP-1 use may be avoidable when people adopt lasting habit changes.

IMM Is Proven

Our method uses shame-free, performance-neutral habit loops that strengthen over time — even for high-risk individuals.

Real Employer Data In a recent pilot with a Fortune 5 national retailer, Fresh Tri drove:

FAQs

Does It Work?

Yes! Neurosicence-backed behavior change creates measurable impact.

How is Fresh Tri different?

The Fresh Tri solution uses proven brain science, not just coaching or performative trends, to nurture real, sustainable habit formation.

Is it credible?

Yes! The innovation was developed by Dr. Kyra Bobinet, a Harvard-trained physician and neuroscientist.

Want to see how much Fresh Tri could save your organization?

Call the Fresh Tri team and book a pilot.

Projection Methodology

Cost projections based on EBRI, BCBS, and Evernorth industry data (2025). Fresh Tri scenario models theoretical impact of sustainable behavior change addressing metabolic root causes (obesity, stress, sedentary lifestyle) that drive demand for weight management pharmaceuticals. Actual outcomes may vary by population and program engagement.